(EW) Edwards Lifesciences - NYSE
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 49.006m USD | Total Return: 18.3% in 12m
Avg Turnover: 425M
EPS Trend: 60.5%
Qual. Beats: 1
Rev. Trend: 84.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Shakeout
Edwards Lifesciences Corporation focuses on specialized medical technologies for structural heart disease and critical care monitoring. The company’s portfolio is centered on the SAPIEN transcatheter aortic valve replacement (TAVR) system, alongside its PASCAL and EVOQUE brands designed for mitral and tricuspid valve repair and replacement.
Operating within the high-barrier Health Care Equipment sector, the company utilizes a direct sales model to supply hospitals and surgical centers globally. Its business model relies heavily on research and development to maintain its position in the minimally invasive cardiovascular market, where aging global demographics drive long-term demand for heart valve therapies.
Investors can access further technical analysis and valuation metrics on ValueRay to assist in their due diligence. Founded in 1958 and headquartered in Irvine, California, the company maintains a significant international footprint with distribution across Europe, Japan, and emerging markets.
- SAPIEN valve adoption drives transcatheter aortic valve replacement revenue growth
- EVOQUE system commercialization expands leadership in tricuspid valve repair market
- RESILIA tissue technology adoption maintains surgical structural heart profit margins
- CMS reimbursement policy changes impact domestic procedure volume and pricing
- International regulatory approvals determine expansion speed in European and Japanese markets
| Net Income: 1.09b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.08 > 1.0 |
| NWC/Revenue: 76.46% < 20% (prev 86.98%; Δ -10.52% < -1%) |
| CFO/TA 0.10 > 3% & CFO 1.36b > Net Income 1.09b |
| Net Debt (-2.87b) to EBITDA (1.90b): -1.51 < 3 |
| Current Ratio: 4.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (580.7m) vs 12m ago -1.21% < -2% |
| Gross Margin: 77.99% > 18% (prev 79.16%; Δ -1.17% > 0.5%) |
| Asset Turnover: 47.86% > 50% (prev 42.53%; Δ 5.32% > 0%) |
| Interest Coverage Ratio: 85.34 > 6 (EBIT TTM 1.74b / Interest Expense TTM 20.4m) |
| A: 0.36 (Total Current Assets 6.23b - Total Current Liabilities 1.41b) / Total Assets 13.3b |
| B: 1.10 (Retained Earnings 14.6b / Total Assets 13.3b) |
| C: 0.13 (EBIT TTM 1.74b / Avg Total Assets 13.2b) |
| D: 3.45 (Book Value of Equity 10.3b / Total Liabilities 2.99b) |
| Altman-Z'' = 10.46 = AAA |
| DSRI: 1.14 (Receivables 973.0m/751.9m, Revenue 6.30b/5.54b) |
| GMI: 1.02 (GM 79.16% / 77.99%) |
| AQI: 1.01 (AQ_t 0.39 / AQ_t-1 0.39) |
| SGI: 1.14 (Revenue 6.30b / 5.54b) |
| TATA: -0.02 (NI 1.09b - CFO 1.36b) / TA 13.3b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of June 19, 2026, the stock is trading at USD 87.36 with a total of 2,583,882 shares traded.
Over the past week, the price has changed by +0.81%,
over one month by +5.21%,
over three months by +2.86% and
over the past year by +18.30%.
Edwards Lifesciences has received a consensus analysts rating of 3.69. Therefore, it is recommended to hold EW.
- StrongBuy: 10
- Buy: 4
- Hold: 17
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 96.9 | 10.9% |
P/E Trailing = 46.0054
P/E Forward = 28.3286
P/S = 7.8813
P/B = 4.7452
P/EG = 2.045
Revenue TTM = 6.30b USD
EBIT TTM = 1.74b USD
EBITDA TTM = 1.90b USD
Long Term Debt = 598.5m USD (from longTermDebt, last quarter)
Short Term Debt = 24.3m USD (from shortTermDebt, last quarter)
Debt = 807.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 104.4m
Net Debt = -2.87b USD (calculated: Debt 807.3m - CCE 3.67b)
Enterprise Value = 46.1b USD (49.0b + Debt 807.3m - CCE 3.67b)
Interest Coverage Ratio = 85.34 (Ebit TTM 1.74b / Interest Expense TTM 20.4m)
EV/FCF = 42.35x (Enterprise Value 46.1b / FCF TTM 1.09b)
FCF Yield = 2.36% (FCF TTM 1.09b / Enterprise Value 46.1b)
FCF Margin = 17.28% (FCF TTM 1.09b / Revenue TTM 6.30b)
Net Margin = 17.34% (Net Income TTM 1.09b / Revenue TTM 6.30b)
Gross Margin = 77.99% ((Revenue TTM 6.30b - Cost of Revenue TTM 1.39b) / Revenue TTM)
Gross Margin QoQ = 78.21% (prev 78.30%)
Tobins Q-Ratio = 3.46 (Enterprise Value 46.1b / Total Assets 13.3b)
Interest Expense / Debt = 2.53% (Interest Expense 20.4m / Debt 807.3m)
Taxrate = 17.33% (224.9m / 1.30b)
NOPAT = 1.44b (EBIT 1.74b * (1 - 17.33%))
Current Ratio = 4.42 (Total Current Assets 6.23b / Total Current Liabilities 1.41b)
Debt / Equity = 0.08 (Debt 807.3m / totalStockholderEquity, last quarter 10.3b)
Debt / EBITDA = -1.51 (Net Debt -2.87b / EBITDA 1.90b)
Debt / FCF = -2.63 (Net Debt -2.87b / FCF TTM 1.09b)
Total Stockholder Equity = 10.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.30% (Net Income 1.09b / Total Assets 13.3b)
RoE = 10.55% (Net Income TTM 1.09b / Total Stockholder Equity 10.4b)
RoCE = 15.90% (EBIT 1.74b / Capital Employed (Equity 10.4b + L.T.Debt 598.5m))
RoIC = 12.39% (NOPAT 1.44b / Invested Capital 11.6b)
WACC = 7.32% (E(49.0b)/V(49.8b) * Re(7.41%) + D(807.3m)/V(49.8b) * Rd(2.53%) * (1-Tc(0.17)))
Discount Rate = 7.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.11 | Cagr: -1.94%
[DCF] Terminal Value 75.87% ; FCFF base≈1.08b ; Y1≈1.11b ; Y5≈1.24b
[DCF] Fair Price = 38.30 (EV 19.2b - Net Debt -2.87b = Equity 22.1b / Shares 575.8m; r=8.35% [WACC [floored]]; 5y FCF grow 3.29% → 2.50% )
EPS Correlation: 60.49 | EPS CAGR: 1.54% | SUE: 1.28 | # QB: 1
Revenue Correlation: 84.94 | Revenue CAGR: 6.17% | SUE: 0.28 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.74 | Chg30d=+0.08% | Revisions=+0% | Analysts=23
EPS next Quarter (2026-09-30): EPS=0.74 | Chg30d=-0.03% | Revisions=-40% | Analysts=23
EPS current Year (2026-12-31): EPS=3.01 | Chg30d=+0.04% | Revisions=+0% | GrowthEPS=+17.5% | GrowthRev=+11.2%
EPS next Year (2027-12-31): EPS=3.37 | Chg30d=+0.13% | Revisions=+43% | GrowthEPS=+12.0% | GrowthRev=+9.8%
[Analyst] Revisions Ratio: +43%